New drug guselkumab shows promise for Crohn's in early trial
NCT ID NCT04397263
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 study tested the safety of guselkumab in 38 people with moderate-to-severe Crohn's disease. Participants received the drug first through an IV, then as injections. The main goal was to track side effects, but researchers also looked at whether symptoms improved. Results could help determine if guselkumab is a safe option for controlling Crohn's disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Guselkumab (a drug given by IV and then injection)
What this could lead to
If successful, this could provide a new treatment option to help control moderate-to-severe Crohn's disease symptoms and reduce inflammation.
What could go wrong
This is a small, open-label study focused on safety, so results may not confirm effectiveness. Side effects like infections or injection reactions are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHNS DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asahikawa Medical University Hospital
Hokkaido, 078 8510, Japan
-
Hitachi General Hospital
Hitachi, 317-0077, Japan
-
Hyogo Medical University Hospital
Nishinomiya Shi, 663 8501, Japan
-
Institute of Science Tokyo Hospital
Bunkyō City, 113 8519, Japan
-
Ishida Clinic of IBD and Gastroenterology
Ōita, 870 0823, Japan
-
Japanese Red Cross Kumamoto Hospital
Kumamoto, 861-8520, Japan
-
Jichi Medical University Hospital
Shimotsuke, 329-0498, Japan
-
KOKIKAI Tokatsu Tsujinaka Hospital
Abiko, 270-1168, Japan
-
Kenseikai Dongo Hospital
Nara, 635-0022, Japan
-
Kishiwada Tokushukai Hospital
Kishiwada, 5960042, Japan
-
Kitasato University Hospital
Sagamihara, 252-0375, Japan
-
Kumamoto University Hospital
Kumamoto, 860-8556, Japan
-
Kyorin University Hospital
Mitaka, 181-8611, Japan
-
National Center for Global Health and Medicine
Shinjuku- Ku, 162-8655, Japan
-
National Hospital Organization Toyohashi Medical Center
Toyohashi, 441-8570, Japan
-
Ofuna Chuo Hospital
Kamakura, 247-0056, Japan
-
Okayama University Hospital
Okayama, 700-8558, Japan
-
Osaka Medical and Pharmaceutical University Hospital
Takatsuki, 569-8686, Japan
-
Saga University Hospital
Saga, 849-8501, Japan
-
Saitama Medical Center
Saitama, 350 8550, Japan
-
Sapporo Tokushukai Hospital
Sapporo, 004-0041, Japan
-
Sendai Kosei Hospital
Sendai Miyagi, 9810914, Japan
-
Tokyo Metropolitan Bokutoh Hospital
Sumida Ku, 130 8575, Japan
-
Tokyo Women's Medical University Hospital
Shinjuku-ku, 162-8666, Japan
-
Toyama Prefectural Central Hospital
Toyama, 9308550, Japan